Tri Locum Partners LP Protagonist Therapeutics, Inc Transaction History

Tri Locum Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $1.8 Million - $2.93 Million	-99,702 Reduced 74.71%	33,750 $932,000
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $1.44 Million - $3.39 Million	133,452 New	133,452 $3.07 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $10.6 Million - $16.4 Million	455,321 Added 145.04%	769,250 $18.2 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $5.53 Million - $11.6 Million	313,929 New	313,929 $10.7 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $4.42 Million - $17 Million	-341,650 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $2.16 Million - $3.8 Million	84,564 Added 32.89%	341,650 $15.3 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $41,786 - $68,436	-2,197 Reduced 0.85%	257,086 $6.66 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $4.79 Million - $6.52 Million	259,283 New	259,283 $5.23 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.